ME3221, a Surmountable Angiotensin AT1-Receptor Antagonist, Prevents Hypertensive Complications in Aged Stroke-Prone Spontaneously Hypertensive Rats.

DOI Web Site Web Site PubMed 参考文献54件
  • Nagura Jun
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
  • Hui Chen
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
  • Yamamoto Mikio
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
  • Yasuda Sumie
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
  • Abe Mitsuhiro
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
  • Hachisu Mitsugu
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
  • Konno Fukio
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.

この論文をさがす

抄録

The protective effects of ME3221, 3-met hoxy-2, 6-dimethyl-4-[[2''-(1H-tetrazol-5-yl)-1, 1''-biphenyl-4-yl]methoxy] pyridine, on aged (32-week-old) stroke-prone spontaneously hypertensive rats (SHRSP) were studied following long-term (for 8 months) oral administration. At a dose of 10 mg/kg/day, ME3221 suppressed the mortality and the hypertensive complications observed in control SHRSP: cerebral apoplexy (hemorrhage, and spongeform and malacia in the cerebral cortex), increased proteinuria, and total N-acetyl-β-D-glucosaminidase activity, and cardiac hypertrophy and pleural effusion. The protective activity of ME3221, a surmountable angiotensin AT1-receptor antagonist, was comparable to losartan, an insurmountable AT1-antagonist, and also to enalapril, an angiotensin-converting enzyme inhibitor. In addition, ME3221 reduced the systolic blood pressure more effectively than the two reference drugs.

収録刊行物

  • Jpn.J.Pharmacol.

    Jpn.J.Pharmacol. 71 (1), 39-49, 1996

    公益社団法人 日本薬理学会

参考文献 (54)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ